Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers. 

Beauty care improves mental health, quality of life in breast cancer patients

06 Jan 2019
Most of the products involved were not categorised as cosmetics, but were actually pharmaceutical products, which are not registered under the Drug Control Authority.

Beauty care appears to yield short-term and midterm improvements in psychosocial outcomes in patients with early breast cancer, a recent study has found.

The study included 39 female primary breast cancer patients who were randomly assigned to an immediate intervention (n=20; mean age 39.6±9.35 years) or waitlist control (n=19; mean age 37.4±9.60 years) group. The intervention involved a group makeup workshop, a photo session and the receipt of professionally edited photographs.

The intervention had immediate benefits on depressive symptoms. Mean scores dropped from 20.0±5.03 at the start of the session to 15.1±3.33 by the end (p<0.001).

Researchers also observed a short-term benefit of the beauty care intervention. Depressive symptoms were significantly reduced by the first follow-up, which occurred after the immediate intervention but not in the waitlist group had undergone the workshop (MD, –11.9; p=0.001).

This effect persisted until the second follow-up, which took place after the immediate intervention but not in the waitlist group who had received their photos (MD, –8.10; p=0.006). Baseline depressive symptom scores were statistically comparable between the groups (MD, –4.12; p=0.229).

Notably, scores did not differ between the second and third follow-up sessions for both groups, indicating that scores had stabilized by this point.

Similar trends were observed for quality of life, which was significantly higher in the immediate intervention group at both the first (MD, 16.8; p=0.010) and second (MD, 16.7; p=0.009) follow-ups. Baseline values were comparable between groups (MD, 7.85; p=0.271).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
15 Mar 2019
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.